[The logo is protected from the company]
DARA Biosciences, Inc.
DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. * Sharpened focus in oncology as a result of the acquisition with Oncogenerix, Inc. (January 2012): o Near-term revenue generating opportunity with Soltamox®, a novel oral liquid tamoxifen*. + Only oral liquid therapy for breast cancer approved by the FDA. o Planned development of a portfolio of sterile injectable generic chemotherapeutic drugs (cytotoxics). o Other potential revenue producing opportunities * DARA’s proprietary pipeline: o Novel Phase II drug targeted at chemotherapy- induced neuropathic pain (CIPN). + Area of significant unmet medical need, + Market potential estimated at $2.5B - $2.9B for CIPN * Partnering & out-licensing opportunities. o DB959 and other novel clinical compounds in diabetes and a library of patented compounds across a range of therapeutic areas* Licensed from Rosemont Pharmaceuticals (Leeds, UK)
|Address||8601 Six Forks Road Suite 160 Raleigh, NC 27615 USA|
|Holding||No Holding Details|
Open Jobs - DARA Biosciences, Inc.
Currently there are no opneings at DARA Biosciences, Inc.
DARA Biosciences, Inc. Reviews
No Reviews yet.